Compare Quest Diagnostics Inc (DGX) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Zillow Group Inc Class C — how do they compare? Quest Diagnostics Inc trades at $230.78 (market cap $25.48B), while Zillow Group Inc Class C trades at $28.73 (market cap $6.59B). The key difference: Quest Diagnostics Inc is far larger — about 3.9× Zillow Group Inc Class C's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Zillow Group Inc Class C for 39 Days on average.
| DGX | Z | |
|---|---|---|
Market Cap | $25.48B | $6.59B |
Volume | 941,866 | 9,134,294 |
Sector | Health | Media |
52-Week High | $247.45 | $78.04 |
52-Week Low | $173.49 | $27.13 |
Typical Hold Time | 56 Days | 39 Days |
Enterprise Value | $31.23B | $6.47B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Zillow Group (Z) trades at $28.65, up 5.02% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported revenue of $2.58 billion in 2025, turning a net profit of $23 million after a loss in 2024, and shows improving margins. Recent news highlights AI integration in real estate and resolution of an FTC lawsuit, while the housing market faces affordability challenges.
The outlook is cautiously optimistic with a consensus price target of $60.33, implying significant upside, but risks include sensitivity to mortgage rates and competitive pressures. Earnings have beaten expectations in two of the last three quarters, supporting growth potential amid a volatile housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
